Literature DB >> 22841521

A comparison of osteoprotegerin with adiponectin and high-sensitivity C-reactive protein (hsCRP) as a marker for insulin resistance.

Eoin P O'Sullivan1, David T Ashley, Colin Davenport, Lakshmi Penugonda, Grainne Kelleher, Niamh Devlin, Rachel Crowley, Paula O'Shea, Amar Agha, Chris J Thompson, Donal J O'Gorman, Diarmuid Smith.   

Abstract

OBJECTIVE: Insulin resistance (IR) is associated with low adiponectin and elevated high sensitivity C-reactive protein (hsCRP). Osteoprotegerin (OPG) has been shown to be elevated in type 2 diabetes, but whether it reflects underlying IR is unclear. We aimed to compare the ability of serum OPG with adiponectin and hsCRP to act as a marker for IR in individuals with normal and abnormal glucose tolerance. MATERIALS/
METHODS: 115 men underwent a 75 g oral glucose tolerance test. OPG, hsCRP and adiponectin were measured using ELISA. IR was assessed using the homeostasis model assessment of insulin resistance (HOMA-IR).
RESULTS: Men with abnormal glucose tolerance (n=38) were older (58.3±11.2 vs 47.3±11.4 years, P<.001), had higher body mass index (BMI) (31.1±2.9 vs 27.9±3.2 kg/m(2), P<.001) and were more insulin resistant (median (I.Q.) HOMA-IR 5.88 (3.38) vs 1.13 (1.14), P<.001) than those with normal glucose tolerance (n=77). After adjustment for age and BMI, OPG (6.28 (2.32) vs 5.16 (1.86) pmol/L, P<.001) and hsCRP (2.07 (5.47) vs 0.78 (1.05) mg/L, P<.001) were higher and adiponectin (3.02±1.17 vs 4.78±2.38 μg/mL, P<.001) was lower in those with AGT. After adjustment for age and BMI, adiponectin (r=-0.317, P<.001) and hsCRP (r=0.318, P<.001), but not OPG (r=0.126, P=.196) correlated with HOMA-IR. On multiple linear regression analysis, adiponectin and hsCRP but not OPG were independent predictors of HOMA-IR.
CONCLUSIONS: OPG is higher in individuals with abnormal glucose tolerance, but unlike adiponectin and hsCRP, does not correlate with HOMA-IR, suggesting its elevation within this cohort of individuals is due to factors other than insulin resistance.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22841521     DOI: 10.1016/j.metabol.2012.06.005

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  9 in total

1.  Parathyroid hormone (1-34) promotes fracture healing in ovariectomized rats with type 2 diabetes mellitus.

Authors:  G Y Liu; G L Cao; F M Tian; H P Song; L L Yuan; L D Geng; Z Y Zheng; L Zhang
Journal:  Osteoporos Int       Date:  2017-08-14       Impact factor: 4.507

2.  Loss of Hdac3 in osteoprogenitors increases bone expression of osteoprotegerin, improving systemic insulin sensitivity.

Authors:  Meghan E McGee-Lawrence; Jessica L Pierce; Kanglun Yu; Natasha R Culpepper; Elizabeth W Bradley; Jennifer J Westendorf
Journal:  J Cell Physiol       Date:  2017-09-12       Impact factor: 6.384

3.  Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.

Authors:  Muyesser Sayki Arslan; Esra Tutal; Mustafa Sahin; Melia Karakose; Bekir Ucan; Gulfer Ozturk; Erman Cakal; Zeynep Biyikli Gencturk; Mustafa Ozbek; Tuncay Delibasi
Journal:  Endocrine       Date:  2016-10-15       Impact factor: 3.633

4.  Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes.

Authors:  Raelene E Maser; M James Lenhard; Michael B Sneider; Ryan T Pohlig
Journal:  Endocr Pract       Date:  2015-01       Impact factor: 3.443

5.  The association of insulin resistance with serum osteoprotegerin in obese adolescents.

Authors:  Joanna Suliburska; Pawel Bogdanski; Ewa Gajewska; Grazyna Kalmus; Magdalena Sobieska; Wlodzimierz Samborski
Journal:  J Physiol Biochem       Date:  2013-05-22       Impact factor: 4.158

Review 6.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

7.  Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION study.

Authors:  Yixin Niu; Zhen Yang; Xiaoyong Li; Weiwei Zhang; Shuai Lu; Hongmei Zhang; Xueru Chen; Lingfei Zhu; Yin Xing; Guang Ning; Li Qin; Qing Su
Journal:  BMC Endocr Disord       Date:  2015-12-01       Impact factor: 2.763

8.  Serum Osteoprotegerin Is a Potential Biomarker of Insulin Resistance in Chinese Postmenopausal Women with Prediabetes and Type 2 Diabetes.

Authors:  Peng Duan; Min Yang; Meilin Wei; Jia Liu; Ping Tu
Journal:  Int J Endocrinol       Date:  2017-01-31       Impact factor: 3.257

Review 9.  Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease.

Authors:  Lucia Pacifico; Gian Marco Andreoli; Miriam D'Avanzo; Delia De Mitri; Pasquale Pierimarchi
Journal:  World J Gastroenterol       Date:  2018-05-21       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.